

# Christen Bertel Lykkegaard Andersen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1318646/publications.pdf>

Version: 2024-02-01

62  
papers

1,354  
citations

516710

16  
h-index

377865

34  
g-index

65  
all docs

65  
docs citations

65  
times ranked

2374  
citing authors

#	ARTICLE	IF	CITATIONS
1	A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2022, 112, 106756.	0.8	3
2	Biochemical abnormalities among patients referred for celiac disease antibody blood testing in a primary health care setting. <i>Scientific Reports</i> , 2022, 12, 6407.	3.3	4
3	A retrospective cohort study of patients with eosinophilia referred to a tertiary centre.. <i>Danish Medical Journal</i> , 2022, 69, .	0.5	0
4	Pre-diagnostic trajectories of lymphocytosis predict time to treatment and death in patients with chronic lymphocytic leukemia. <i>Communications Medicine</i> , 2022, 2, .	4.2	2
5	MO518: Chronic Kidney Disease in Primary Care and the Risk of Cardiovascular Comorbidity and Mortality. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
6	Incidence of New-Onset Type 2 Diabetes After Cancer: A Danish Cohort Study. <i>Diabetes Care</i> , 2022, 45, e105-e106.	8.6	7
7	Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival. <i>British Journal of Haematology</i> , 2021, 192, e81-e84.	2.5	2
8	Influence of educational level on test and treatment for incident hypothyroidism. <i>Clinical Endocrinology</i> , 2021, 94, 1025-1034.	2.4	4
9	Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic. <i>Covid</i> , 2021, 1, 303-314.	1.5	0
10	Risk of over- and under- treatment with levothyroxine in primary care in Copenhagen, Denmark. <i>European Journal of Endocrinology</i> , 2021, 185, 673-679.	3.7	9
11	Labor Market Attachment in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study. <i>Blood</i> , 2021, 138, 3627-3627.	1.4	0
12	Strategies to improve patient-reported outcome completion rates in longitudinal studies. <i>Quality of Life Research</i> , 2020, 29, 335-346.	3.1	27
13	Age-related prevalence and clinical significance of neutropenia –isolated or combined with other cytopenias: Real world data from 373%820 primary care individuals. <i>American Journal of Hematology</i> , 2020, 95, 521-528.	4.1	10
14	Health-Related Quality of Life in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Nationwide Population-Based Survey in Denmark. <i>Cancers</i> , 2020, 12, 3565.	3.7	10
15	Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association. <i>Cancers</i> , 2020, 12, 2202.	3.7	13
16	The Copenhagen Primary Care Laboratory Pregnancy (CopPreg) database. <i>BMJ Open</i> , 2020, 10, e034318.	1.9	6
17	Ruxolitinib and interferon- $\gamma$ combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. <i>Haematologica</i> , 2020, 105, 2262-2272.	3.5	67
18	Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. <i>Clinical Epidemiology</i> , 2019, Volume 11, 23-33.	3.0	18

#	ARTICLE	IF	CITATIONS
19	Association of the blood eosinophil count with end-organ symptoms. <i>Annals of Medicine and Surgery</i> , 2019, 45, 11-18.	1.1	11
20	Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. <i>Experimental Hematology</i> , 2019, 79, 26-34.	0.4	8
21	Epstein-Barr virus and its association with disease - a review of relevance to general practice. <i>BMC Family Practice</i> , 2019, 20, 62.	2.9	108
22	Changes in Prescription Routines for Treating Hypothyroidism Between 2001 and 2015: An Observational Study of 929,684 Primary Care Patients in Copenhagen. <i>Thyroid</i> , 2019, 29, 910-919.	4.5	43
23	Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 2549-2557.	1.3	5
24	Clarithromycin added to bortezomib+cyclophosphamide+dexamethasone impairs health-related quality of life in multiple myeloma patients. <i>European Journal of Haematology</i> , 2019, 102, 70-78.	2.2	8
25	Thromboembolism prophylaxis in patients with Philadelphia-negative myeloproliferative neoplasms-Clinical practice among Nordic specialists. <i>European Journal of Haematology</i> , 2018, 100, 475-478.	2.2	1
26	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2018, 379, 1416-1430.	27.0	442
27	The development of multimorbidity during 16 years after diagnosis of type 2 diabetes. <i>Journal of Comorbidity</i> , 2018, 8, 2235042X1880165.	3.9	12
28	Brain Natriuretic Peptide in Plasma as Predictor of All-Cause Mortality in a Large Danish Primary Health Care Population Suspected of Heart Failure. <i>Clinical Chemistry</i> , 2018, 64, 1723-1731.	3.2	9
29	Safety and efficacy of combination therapy of interferon- $\alpha$ 2 and ruxolitinib in polycythemia vera and myelofibrosis. <i>Cancer Medicine</i> , 2018, 7, 3571-3581.	2.8	38
30	Interpretation of HbA <sub>1c</sub> in primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database. <i>Diabetic Medicine</i> , 2018, 35, 1700-1706.	2.3	19
31	A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. <i>Experimental Hematology and Oncology</i> , 2018, 7, 18.	5.0	9
32	A systematic review of health-related quality of life in longitudinal studies of myeloma patients. <i>European Journal of Haematology</i> , 2017, 99, 3-17.	2.2	54
33	Anemia is present years before myelodysplastic syndrome diagnosis: Results from the pre-diagnostic period. <i>American Journal of Hematology</i> , 2017, 92, E130-E132.	4.1	5
34	Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations. <i>Scientific Reports</i> , 2017, 7, 6774.	3.3	16
35	A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents. <i>Clinical Epidemiology</i> , 2017, Volume 9, 141-150.	3.0	8
36	The Danish National Chronic Myeloid Neoplasia Registry. <i>Clinical Epidemiology</i> , 2016, Volume 8, 567-572.	3.0	11

#	ARTICLE	IF	CITATIONS
37	Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study. <i>Journal of Internal Medicine</i> , 2016, 279, 566-575.	6.0	31
38	A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms. <i>Quality of Life Research</i> , 2016, 25, 835-846.	3.1	15
39	Health-Related Quality of Life (HRQoL) Measurements in Multiple Myeloma Patients Obtained By EORTC QLQ-C30; A Critical Review of Interpreting HRQoL Data in Longitudinal Studies. <i>Blood</i> , 2016, 128, 540-540.	1.4	1
40	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. <i>Blood</i> , 2016, 128, 5479-5479.	1.4	0
41	Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. <i>Oncotarget</i> , 2015, 6, 40588-40597.	1.8	14
42	Association of the blood eosinophil count with hematological malignancies and mortality. <i>American Journal of Hematology</i> , 2015, 90, 225-229.	4.1	20
43	Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer?. <i>Gynecologic Oncology</i> , 2015, 139, 312-318.	1.4	10
44	Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study. <i>Blood</i> , 2015, 126, 824-824.	1.4	14
45	The Copenhagen Primary Care Differential Count (CopDiff) database. <i>Clinical Epidemiology</i> , 2014, 6, 199.	3.0	16
46	Eosinophilia in routine blood samples as a biomarker for solid tumor development – A study based on The Copenhagen Primary Care Differential Count (CopDiff) Database. <i>Acta Oncologica</i> , 2014, 53, 1245-1250.	1.8	9
47	A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. <i>Haematologica</i> , 2014, 99, e5-e7.	3.5	22
48	Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. <i>European Journal of Haematology</i> , 2014, 93, 224-228.	2.2	21
49	The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2014, 38, 334-339.	0.8	5
50	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. <i>Leukemia Research</i> , 2014, 38, 816-821.	0.8	12
51	Risk of Lymphoma and Solid Cancer among Patients with Rheumatoid Arthritis in a Primary Care Setting. <i>PLoS ONE</i> , 2014, 9, e99388.	2.5	15
52	Prediagnostic Thrombocytosis Increases the Risk of Advanced Gynecological Cancer and Increases Mortality Independently of Cancer Stage – a Population-Based Study. <i>Blood</i> , 2014, 124, 2791-2791.	1.4	0
53	DNA Methylation Profiling of Sorted Cells from Myelofibrosis Patients reveals Aberrant Epigenetic Regulation of Immune Pathways and identifies Early MPN Driver Genes. <i>Blood</i> , 2014, 124, 4576-4576.	1.4	0
54	A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2013, 162, 498-508.	2.5	65

#	ARTICLE	IF	CITATIONS
55	Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. <i>Leukemia Research Reports</i> , 2013, 2, 1-3.	0.4	30
56	Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death. <i>American Journal of Hematology</i> , 2013, 88, 843-847.	4.1	33
57	Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial. <i>Blood</i> , 2013, 122, 4090-4090.	1.4	7
58	Risks of Eosinophil-Related End-Organ Damage, Hematological Malignancies and Death Are Significantly Increased Even below Consensus Threshold Criteria for Blood Eosinophilia. <i>Blood</i> , 2013, 122, 2831-2831.	1.4	1
59	Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms. <i>Leukemia Research</i> , 2012, 36, 485-487.	0.8	6
60	Symptom Burden Among PV and ET Patients Receiving A Novel Histone Deacetylase Inhibitor: Findings From a Open-Label Phase II Study. <i>Blood</i> , 2012, 120, 1736-1736.	1.4	1
61	A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2012, 120, 803-803.	1.4	4
62	Systemic mastocytosis--a systematic review. <i>Danish Medical Journal</i> , 2012, 59, A4397.	0.5	12